Literature DB >> 24670341

Multiple colon perforation as a fatal complication during treatment of metastatic melanoma with ipilimumab - case report.

Paweł Dilling, Jakub Walczak, Paweł Pikiel, Wiesław J Kruszewski.   

Abstract

Ipilimumab, an anticancer drug, is an anti-CTLA4 monoclonal antibody. It is used in treatment of disseminated melanoma. Therapy is associated with high risk of complications. One of the most serious, although one of the rarest is perforation of gastrointestinal tract. In this case report we describe a 52-year old male, with disseminated melanoma with unknown starting point, treated with anti- CTLA4 monoclonal antibody. After 3rd dose of drug administration, bloody diarrhea and acute abdominal pain occurred as a symptom of gastrointestinal perforation. A single perforation was sutured during laparotomy. Symptoms of acute abdomen returned after 10 days. Pus-faecalperitonitis, symptoms of necro-hemorrhagic colitis and multilocal perforation of the colon were found during relaparotomy. Pancolectomy with end ileostomy was performed. Few hours since relaparotomy pacient died due to multiple organ failure. The purpose of this case report is to draw attention to a risk of multilocal colon perforation in patient treated with ipilumumab.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24670341     DOI: 10.2478/pjs-2014-0017

Source DB:  PubMed          Journal:  Pol Przegl Chir        ISSN: 0032-373X


  9 in total

1.  Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection.

Authors:  Gurhan Sisman; Erol Barbur; Didem Saka; Sibel Erdamar Cetin
Journal:  Cancer Immunol Immunother       Date:  2021-01-22       Impact factor: 6.968

Review 2.  New clinical advances in immunotherapy for the treatment of solid tumours.

Authors:  Valentina A Zavala; Alexis M Kalergis
Journal:  Immunology       Date:  2015-03-30       Impact factor: 7.397

3.  Ipilimumab as a Cause of Severe Pan-Colitis and Colonic Perforation.

Authors:  Raj Shah; Danielle Witt; Talal Asif; Fahad F Mir
Journal:  Cureus       Date:  2017-04-20

4.  Anti-PD-1 Therapy-Associated Perforating Colitis.

Authors:  Romulo Celli; Harriet M Kluger; Xuchen Zhang
Journal:  Case Rep Gastrointest Med       Date:  2018-05-31

Review 5.  Immune checkpoint inhibitor-induced colitis: A comprehensive review.

Authors:  Aniruddh Som; Rohan Mandaliya; Dana Alsaadi; Maham Farshidpour; Aline Charabaty; Nidhi Malhotra; Mark C Mattar
Journal:  World J Clin Cases       Date:  2019-02-26       Impact factor: 1.337

Review 6.  Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases.

Authors:  Sandra Assoun; Virginie Lemiale; Elie Azoulay
Journal:  Intensive Care Med       Date:  2019-05-29       Impact factor: 17.440

Review 7.  Biologic Therapy for Refractory Immune Checkpoint Inhibitor Colitis.

Authors:  Nasser M Alorfi; Mansour Marzouq Alourfi
Journal:  Biologics       Date:  2022-08-05

Review 8.  Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: A comprehensive review.

Authors:  Hua Li; Zhi-Yan Fu; Mustafa Erdem Arslan; Daniel Cho; Hwajeong Lee
Journal:  World J Exp Med       Date:  2021-12-30

Review 9.  Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.

Authors:  Anne Bertrand; Marie Kostine; Thomas Barnetche; Marie-Elise Truchetet; Thierry Schaeverbeke
Journal:  BMC Med       Date:  2015-09-04       Impact factor: 8.775

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.